Recent events
Recent events tied to this brand in public sources.
Back to profile5 entries
2021
FDA approves Opzelura for atopic dermatitis
The FDA approved Incyte's Opzelura cream for atopic dermatitis in non-immunocompromised patients; the article says it is indicated for patients aged 12 and older whose disease is not adequately controlled with other topical prescription products.
2021
FDA approves Jakafi for chronic GVHD
The FDA approved ruxolitinib (Jakafi, Incyte) for certain patients aged 12 years or older with chronic graft-versus-host disease who failed one or two lines of systemic therapy.
2020
FDA approves Monjuvi with lenalidomide for certain DLBCL patients
MorphoSys and Incyte announced that the FDA approved Monjuvi (tafasitamab-cxix) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant. The approval was under the accelerated approval program.
2020
FDA approves Pemazyre for cholangiocarcinoma
The U.S. Food and Drug Administration approved Incyte's Pemazyre for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement detected by an FDA-approved test. The approval was under the accelerated approval pathway.
2020
Incyte launches the Incyte Ingenuity Award programme
Incyte opened submissions for its new annual award programme, which will fund one programme, idea or initiative each year to address an unmet need in the graft-versus-host disease community.